Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma.
The company is headquartered in Frederick, Maryland.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 22, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Carsten Brunn |
Contact Details
Address: 7495 New Horizon Way Frederick, Maryland 21703 United States | |
| Phone | 301 348 8698 |
| Website | cartesiantherapeutics.com |
Stock Details
| Ticker Symbol | RNAC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453687 |
| CUSIP Number | 816212302 |
| ISIN Number | US8162123025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Chairman of the Board |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer |
| Dr. Emily English Ph.D. | Chief Operating Officer |
| June Seymour | Chief Accounting Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2026 | SCHEDULE 13G/A | Filing |
| Apr 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 30, 2026 | 10-Q | Quarterly Report |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2026 | SCHEDULE 13D/A | Filing |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 13, 2026 | SCHEDULE 13G | Filing |
| Mar 9, 2026 | 10-K | Annual Report |